Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $22.82 Average PT from Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC) has earned an average rating of “Moderate Buy” from the twelve ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $22.8182.

Several research analysts have recently issued reports on the stock. Loop Capital set a $25.00 price target on shares of Alphatec in a report on Wednesday, December 10th. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, January 31st. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Alphatec in a research note on Monday, January 12th. Lake Street Capital set a $25.00 price objective on Alphatec and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Canaccord Genuity Group raised their price objective on shares of Alphatec from $20.00 to $25.00 and gave the company a “buy” rating in a report on Friday, October 31st.

Insider Transactions at Alphatec

In related news, Director David R. Pelizzon sold 250,000 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $20.62, for a total value of $5,155,000.00. Following the sale, the director owned 10,895,045 shares of the company’s stock, valued at $224,655,827.90. The trade was a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Squadron Capital Llc sold 250,000 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $20.62, for a total value of $5,155,000.00. Following the transaction, the insider directly owned 10,895,045 shares of the company’s stock, valued at approximately $224,655,827.90. This represents a 2.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 2,970,700 shares of company stock worth $61,478,317. Company insiders own 20.90% of the company’s stock.

Hedge Funds Weigh In On Alphatec

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd bought a new position in Alphatec during the 3rd quarter worth approximately $34,000. Osterweis Capital Management Inc. acquired a new stake in shares of Alphatec during the second quarter worth $37,000. Nisa Investment Advisors LLC raised its stake in Alphatec by 22.4% during the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after buying an additional 1,045 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Alphatec during the third quarter worth $73,000. Finally, FNY Investment Advisers LLC acquired a new position in Alphatec in the third quarter valued at $74,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Trading Down 4.2%

Shares of Alphatec stock opened at $14.06 on Monday. The firm’s 50 day moving average is $19.22 and its 200 day moving average is $17.01. The firm has a market capitalization of $2.09 billion, a PE ratio of -13.52 and a beta of 1.01. Alphatec has a 1 year low of $8.81 and a 1 year high of $23.29. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 43.02.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.